Technical Mastery: Guidance on Proper Imaging, Lesion Preparation, and Deployment for Coronary Drug-Coated Balloons. Part 1: In-Stent Restenosis, Step-by-Step How to Treat
How to Register
  1. To register, press the "Get Started" button.
  2. Sign in with your scai.org username and password. If you don't have an account, click “Set Up Your Login.”
Faculty

 

Sahil A. Parikh, MD, FSCAI

Moderator and Speaker

Coronary DCB Clinical Trials: Key Data and Their Implication for Practice 
Kate Kearney, MD, FSCAI

Speaker

Case - Using DCBs to Treat In-Stent Restenosis
Evan Shlofmitz, DO

Speaker

Getting It Right: Using IVUS, Lesions 

Preparation and DCB’s to Treat Stent Failure 
Monica Wright, DPA, MHA, CPC, CPMA, CPCO

Speaker


DCB Billing and Reimbursement
Wayne B. Batchelor, MD, FSCAI

Panelist
Brian Bergmark, MD, FSCAI

Panelist

 

Acknowledgment of Commercial Support
This activity is supported by an unrestricted educational grant from Boston Scientific.
Learning Objectives
Upon completion of this mini-series, participants will be able to:
  • Discuss key data from coronary drug-coated balloon (DCB) clinical trials and their implications for clinical practice.
  • Select appropriate patients for coronary DCB’s.
  • Plan for deployment of coronary DCB’s, including step-by-step imaging guidance and lesions preparation.
  • Examine cases of in-stent restenosis (ISR), including single-layer, double-layer, and stent failure. 
  • Explore other evidence-based applications of coronary DCB’s.
Disclosures
During the development of this activity, the following financial relationships were disclosed:

Planners:
  • Sahil Parikh: Boston Scientific Corp. - Advisory Board/Board Member 

Faculty:
  • Brian Bergmark and Monica Wright: No relevant financial relationships with ineligible companies.
  • Wayne Batchelor: Boston Scientific Corp. - consulting.
  • Kate Kearney: Boston Scientific Corp. - consulting, honorarium.
  • Sahil Parikh: Boston Scientific Corp. - Advisory Board/Board Member.
  • Evan Shlofmitz: Philips – consulting.

SCAI Staff

  • Kristen Perry: No relevant financial relationships with ineligible companies.
Continuing Education Information

Accreditation Statement
The Society for Cardiovascular Angiography & Interventions (SCAI) is accredited by the
Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

​Credit Designation
SCAI designates this live activity for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

​ABIM MOC
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.25 medical knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Successful Completion
Watch the content and complete the evaluation to obtain credit.

Activity Timeline
Recoding date: 8/27/25
Publish date: 9/23/25
Expiration date: 9/23/28

SCAI's Independent Content

As a provider of continuing medical education through the Accreditation Council for Continuing Medical Education (ACCME), it is the Society’s policy to ensure balance, independence, objectivity, and scientific rigor in all its activities.

Planning Process 
SCAI activities are developed by the SCAI planners prior to and independent of commercial support. Members of the Education Committee reviewed and approved this activity. If planners had relevant financial relationships, the agenda was peer reviewed by a member with no relevant financial relationships.

Mitigation of Relevant Financial Relationships
All participating planners, reviewers, faculty, and staff are required to disclose to SCAI all financial relationships with ineligible companies. SCAI identifies relevant financial relationships and mitigates them before the activity begins. 

Content Validation Statement
SCAI accepts the following Content Validation Statements and expects all persons involved in its professional education activities to abide by these statements for clinical care recommendations.

All clinical and pharmacological recommendations are based on evidence accepted within the medical profession as adequate jurisdiction for their indications and contradictions in patient care. SCAI does not promote recommendations, treatment, or manners of practicing medicine that are not within the definition of accredited continuing education or known to have risks or dangers that outweigh the benefits or known to be ineffective in the treatment of patients.

All research referenced to support or justify patient care recommendations conforms to accepted standards of experimental design, data collection and analysis. 

SCAI actively promotes improvements in health care and NOT proprietary interests of an ineligible company. SCAI's educational content is free of marketing or sales of products or services.

Faculty will not actively promote or sell products or services that serve their professional or financial interests during accredited education. 

SCAI encourages faculty to identify investigational products or off-label uses of products regulated by the U.S. Food and Drug Administration (FDA), at first mention and where appropriate in the content.

Copyright
© 2025 Society for Cardiovascular Angiography and Interventions (SCAI). All rights reserved.
Summary
Availability:
On-Demand
Access expires on Sep 24, 2028
Cost:
FREE
Credit Offered:
1.25 CME Credits
1.25 ABIM-MOC Points
1.25 Participation Credits
Powered By